Can a common antioxidant shield kidneys from a powerful antibiotic?
NCT ID NCT07668141
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking alpha-lipoic acid, an antioxidant, can protect the kidneys of hospitalized patients who need the strong antibiotic colistin. Colistin can cause kidney damage, and researchers want to see if this supplement lowers that risk. The trial will involve 88 adults with multidrug-resistant infections and will use a urine biomarker to detect early kidney injury.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alpha-lipoic acid
What this could lead to
If it works, this could offer a simple way to protect kidneys during colistin treatment, reducing the risk of acute kidney injury.
What could go wrong
This is a small, early-phase trial with only 88 participants. The benefit seen in animal studies may not translate to humans, and alpha-lipoic acid may not prevent kidney damage in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTOXICITY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
6th October Hospital-Dokki-General Authority for Health Insurance Organization
Giza, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Al-Haram Hospital
Giza, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••